173 related articles for article (PubMed ID: 30347895)
21. Sialic acid-binding lectin (leczyme) induces caspase-dependent apoptosis-mediated mitochondrial perturbation in Jurkat cells.
Tatsuta T; Hosono M; Sugawara S; Kariya Y; Ogawa Y; Hakomori S; Nitta K
Int J Oncol; 2013 Nov; 43(5):1402-12. PubMed ID: 24008724
[TBL] [Abstract][Full Text] [Related]
22. Estrogen activation of the mitogen-activated protein kinase is mediated by ER-α36 in ER-positive breast cancer cells.
Zhang X; Deng H; Wang ZY
J Steroid Biochem Mol Biol; 2014 Sep; 143():434-43. PubMed ID: 24973581
[TBL] [Abstract][Full Text] [Related]
23. Induction of AMPK activation by N,N'-diarylurea FND-4b decreases growth and increases apoptosis in triple negative and estrogen-receptor positive breast cancers.
Johnson J; Rychahou P; Sviripa VM; Weiss HL; Liu C; Watt DS; Evers BM
PLoS One; 2019; 14(3):e0209392. PubMed ID: 30875375
[TBL] [Abstract][Full Text] [Related]
24. A novel chalcone-based molecule, BDP inhibits MDA‑MB‑231 triple-negative breast cancer cell growth by suppressing Hsp90 function.
Oh YJ; Seo YH
Oncol Rep; 2017 Oct; 38(4):2343-2350. PubMed ID: 28849241
[TBL] [Abstract][Full Text] [Related]
25. Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells.
Oh AS; Lorant LA; Holloway JN; Miller DL; Kern FG; El-Ashry D
Mol Endocrinol; 2001 Aug; 15(8):1344-59. PubMed ID: 11463858
[TBL] [Abstract][Full Text] [Related]
26. Curcumin induces apoptosis of triple-negative breast cancer cells by inhibition of EGFR expression.
Sun XD; Liu XE; Huang DS
Mol Med Rep; 2012 Dec; 6(6):1267-70. PubMed ID: 23023821
[TBL] [Abstract][Full Text] [Related]
27. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
28. Ginsenoside 20(S)-protopanaxadiol inhibits triple-negative breast cancer metastasis in vivo by targeting EGFR-mediated MAPK pathway.
Peng B; He R; Xu Q; Yang Y; Hu Q; Hou H; Liu X; Li J
Pharmacol Res; 2019 Apr; 142():1-13. PubMed ID: 30735802
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of ERBB4 expression in patients with triple negative breast cancer.
Kim JY; Jung HH; Do IG; Bae S; Lee SK; Kim SW; Lee JE; Nam SJ; Ahn JS; Park YH; Im YH
BMC Cancer; 2016 Feb; 16():138. PubMed ID: 26907936
[TBL] [Abstract][Full Text] [Related]
30. Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
Ribas R; Pancholi S; Rani A; Schuster E; Guest SK; Nikitorowicz-Buniak J; Simigdala N; Thornhill A; Avogadri-Connors F; Cutler RE; Lalani AS; Dowsett M; Johnston SR; Martin LA
Breast Cancer Res; 2018 Jun; 20(1):44. PubMed ID: 29880014
[TBL] [Abstract][Full Text] [Related]
31. Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells.
Liu CY; Hu MH; Hsu CJ; Huang CT; Wang DS; Tsai WC; Chen YT; Lee CH; Chu PY; Hsu CC; Chen MH; Shiau CW; Tseng LM; Chen KF
Oncotarget; 2016 Feb; 7(8):9135-49. PubMed ID: 26824320
[TBL] [Abstract][Full Text] [Related]
32. NRF1 motif sequence-enriched genes involved in ER/PR -ve HER2 +ve breast cancer signaling pathways.
Ramos J; Das J; Felty Q; Yoo C; Poppiti R; Murrell D; Foster PJ; Roy D
Breast Cancer Res Treat; 2018 Nov; 172(2):469-485. PubMed ID: 30128822
[TBL] [Abstract][Full Text] [Related]
33. Estrogen receptor β selective agonists reduce invasiveness of triple-negative breast cancer cells.
Hinsche O; Girgert R; Emons G; Gründker C
Int J Oncol; 2015 Feb; 46(2):878-84. PubMed ID: 25420519
[TBL] [Abstract][Full Text] [Related]
34. Differential effect of EGFR inhibitors on tamoxifen-resistant breast cancer cells.
Kim S; Lee J; Oh SJ; Nam SJ; Lee JE
Oncol Rep; 2015 Sep; 34(3):1613-9. PubMed ID: 26166014
[TBL] [Abstract][Full Text] [Related]
35. Erythro-austrobailignan-6 down-regulates HER2/EGFR/integrinβ3 expression via p38 activation in breast cancer.
Han JH; Jeong HJ; Lee HN; Kwon YJ; Shin HM; Choi Y; Lee S; Oh ST; Kim DI; Jeon S
Phytomedicine; 2017 Jan; 24():24-30. PubMed ID: 28160858
[TBL] [Abstract][Full Text] [Related]
36. A novel taspine derivative, HMQ1611, inhibits breast cancer cell growth via estrogen receptor α and EGF receptor signaling pathways.
Zhan Y; Zhang Y; Liu C; Zhang J; Smith WW; Wang N; Chen Y; Zheng L; He L
Cancer Prev Res (Phila); 2012 Jun; 5(6):864-73. PubMed ID: 22496388
[TBL] [Abstract][Full Text] [Related]
37. Modulation of Estrogen α and Progesterone Receptors in Triple Negative Breast Cancer Cell Lines: The Effects of Vorinostat and Indole-3-Carbinol In Vitro.
Nouri Emamzadeh F; Word B; Cotton E; Hawkins A; Littlejohn K; Moore R; Miranda-Carbon G; Orish CN; Lyn-Cook B
Anticancer Res; 2020 Jul; 40(7):3669-3683. PubMed ID: 32620606
[TBL] [Abstract][Full Text] [Related]
38. HDAC inhibition does not induce estrogen receptor in human triple-negative breast cancer cell lines and patient-derived xenografts.
de Cremoux P; Dalvai M; N'Doye O; Moutahir F; Rolland G; Chouchane-Mlik O; Assayag F; Lehmann-Che J; Kraus-Berthie L; Nicolas A; Lockhart BP; Marangoni E; de Thé H; Depil S; Bystricky K; Decaudin D
Breast Cancer Res Treat; 2015 Jan; 149(1):81-9. PubMed ID: 25503779
[TBL] [Abstract][Full Text] [Related]
39. 17β-estradiol-induced growth of triple-negative breast cancer cells is prevented by the reduction of GPER expression after treatment with gefitinib.
Girgert R; Emons G; Gründker C
Oncol Rep; 2017 Feb; 37(2):1212-1218. PubMed ID: 27959426
[TBL] [Abstract][Full Text] [Related]
40. Lapatinib increases motility of triple-negative breast cancer cells by decreasing miRNA-7 and inducing Raf-1/MAPK-dependent interleukin-6.
Hsiao YC; Yeh MH; Chen YJ; Liu JF; Tang CH; Huang WC
Oncotarget; 2015 Nov; 6(35):37965-78. PubMed ID: 26513016
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
